Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Baxter International Inc on Thursday forecast 2018 earnings largely ahead of analysts' estimates and said it would continue to be active on the acquisition front and repurchase more shares through the year.
The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.
Pfizer Inc said on Tuesday it expected to pay tax at an adjusted rate of about 17 percent this year, higher than some investors had expected, sending its shares down more than 3 percent. | Video
Abbott Laboratories said on Wednesday it was not looking at acquisitions this year as the healthcare company looks to ease its debt burden after a spree of deals last year.
Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.
UnitedHealth Group Inc on Tuesday raised its outlook for 2018 earnings per share by more than 16 percent due to the U.S. corporate tax cut and said it will speed up technology investments that aim to cut customer costs.
CVS Health Corp said on Thursday it expects the recent tax reform to boost its cash flow by about $1.2 billion, sending its shares up nearly 5 percent in afternoon trading.
Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.
Orchard Therapeutics said on Wednesday it raised $110 million in the second round of funding as the drug developer looks to launch its gene therapy to treat a rare inherited disorder and beef up manufacturing facilities.
Tenet Healthcare Corp on Tuesday said it is putting its Conifer unit up for sale and plans to cut $100 million more in costs, as its new chief executive works to slash its heavy debt load.